Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)

#1534

Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.

Aim(s): To assess the potential of personalized PRRT to safely increase absorbed radiation dose rate to tumors.

Materials and methods: Twelve NET patients underwent four 177Lu-octreotate induction cycles followed by quantitative SPECT dosimetry. The median activity per cycle was 7.4 (5.6–8.1) GBq. We simulated a personalized PRRT protocol where activity per cycle was adjusted to reach, over 4 cycles, cumulative doses of 23 Gy to the kidney or 2 Gy to the bone marrow (BM), the generally recognized safe dose thresholds.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Del Prete M, Buteau F, Beauregard J,

Keywords: personalized, PRRT, neuroendocrine tumors ,